Monoclonal Antibody KI-67 Defined Growth Fraction in Benign Prostatic Hyperplasia and Prostatic Cancer

Abstract

Growth fractions were assessed immunohistochemically in prostatic tissues with benign glandular hyperplasia (BPH) and in specimens of prostatic cancer using the monoclonal antibody Ki-67. This antibody is specific for a proliferation-associated nuclear antigen. In BPH tissues about 0.3% of nuclei of epithelial cells was reactive with Ki-67. The Ki-67 positive nuclei were distributed equally among the basal and luminal cells of the hyperplastic prostatic acini. In prostatic cancer the Ki-67 defined growth fraction ranged from 0.4% to 9.1% (mean value 2.9%). Cancers with a cribriform growth pattern and tumors composed of solid areas of undifferentiated cancer cells showed the highest growth fraction (average values 4.0%, respectively 7.6%). The investigated four tumors composed of undifferentiated solitary tumor cells with diffuse infiltration of the stroma demonstrated an unexpectedly low growth activity (average 1.2%). In cancers with a glandular growth pattern the Ki-67 defined growth fraction of tumor cells varied from 2.2% to 5%. Compared with other epithelial tumors these values are low, but they are in agreement with the earlier findings on prostatic cancer obtained with 3H-thymidine labeling and bromodeoxyuridine incorporation. The observed variation in the level of Ki-67 defined growth activity partly related to the histological tumor pattern suggests that Ki-67 labeling may serve as a prognostic factor additional to the current histopathological grading criteria of prostatic cancer.